Comprehensive in-depth study which provides detailed analysis of the CMO industry, its recent development and trends.
This report on the China Contract Manufacturing Organizations (CMOs) industry covers regional industry developments, regulatory and legal changes, and reviews China’s major CMO and CDMO companies with facility information, company ownership, background, management and facility capacity and history. This study is based on in-depth research, using public secondary and primary information resources.
This is an on-going project that will be updated in the future to provide trends information, and relevant new in-depth insights into the rapidly growing and changing Chinese biologics industry.
Highlights
- Top Ranked CDMO Facilities in China
- Trends in the importance of Contract Manufacturing of biologics in China
- How CMOs are meeting the increased demand and rapid capacity expansions
- Analysis and Profile Directory of CMOs in China
Topline Findings
- China mAb Therapeutics expected to grow to USD $26 billion by 2030, with CMOs accessing an increasing share of domestic production.
- Pipeline Growth in China is accelerating, including markets for mAb therapeutics and vaccines
- Demand for biologics from domestic developers is increasing at 20% annually
Coverage of Top CMO and CDMO Industry Leaders include:
- 3S Guojian
- Asymchem
- AutekBio
- Boehringer-Ingelheim Shanghai
- Canton Bio
- CC Pharming
- Celgen Pharma
- Celltrion
- Chempartner
- C-Mab
- Genescript
- HJB (Transcenta Holding)
- Jiangsu T-Mab
- JOINN Biologics
- Lonza
- Mabplex, and more
Table of Contents
Companies Mentioned
- 3SBio
- AlphaMab
- Amoy-Top Biotech (subsidiary of Tonghua Dongbao)
- Anhui Anke Biotechnology
- Beigene
- BeigeneJunshi Pharma/Jiangsu Suzhou
- Benemae Pharmaceutical
- Biotech Pharma
- Boehringer-Ingelheim
- CP Guojian Pharmaceutical
- CSPC Pharma
- Celgene Pharma/Shanghai
- Changchun Hi-Tech #2 BCHT
- Changchun Hi-Tech GeneScience
- Changchun Institute
- Chengdu Institute
- Chia Tai Tianqing
- Four Rings
- GSK/Shenzhen
- Gan & Lee
- Generon
- Genor
- Henglius Pharma (a subsidiary of Fosun Pharma)
- Hengrui Pharma/Lianyungang
- Hengrui Pharma/Suzhou
- Hisun
- Huahai Pharma
- Hualan/Beijing
- Hualan/Xinxiang
- Innovent Bio
- JHL biotech
- Jiangsu Wanbang
- Junshi Pharma/Jiangsu, Suzhou
- Junshi Pharma/Ligang, Shanghai
- Kanghong Pharma
- Kelun Pharma
- Lanzhou Institute
- Lee’s Pharma
- Livzon mAb
- Luye Pharma
- Mabtech holding Ltd
- North China
- Pfizer/Hangzhou
- Qilu Pharma
- SL Pharma/Beijing
- SL Pharma/Quebec
- Sanofi/Shenzhen
- ShangPharma (Chempartner)
- Shanghai Institute
- Shanghai Pharma
- Shanghai United Cell/Shanghai
- Simcere Pharma/Jiangsu, Changzhou
- Simcere Pharma/Yantai
- SinoCellTech
- Sinobioway/Tianjin
- Sinovac/Beijing
- Tasly
- Teruisipharm
- Tiantan Biologics
- Tonghua DongBao
- Tot Pharma
- Tri-Prime Gene
- Walvax/Kunming
- Walvax/Taizhou
- Walvax/Yuxi
- Wuhan Institute
- Wuxi Biologics
- Yantai Rongchang (MABPLEX,subsidiary of Yantai Rongchang)
- Zesun Pharma
- Zhuhai Essex